These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 14523284)

  • 1. Structured interruptions of therapy: looking for the best protocol.
    Aiuti F; Giovannetti A
    AIDS; 2003 Oct; 17(15):2257-8. PubMed ID: 14523284
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment interruption in HIV therapy: a SMART strategy?
    Jülg B; Goebel FD
    Infection; 2006 Jun; 34(3):186-8. PubMed ID: 16804667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stopping antiretroviral therapy: role for therapeutic drug monitoring.
    Tommasi C; Nicastri E; Corpolongo A; Ivanovic J; Notari S; Ascenzi P; Andreoni M; Narciso P
    AIDS; 2008 Jan; 22(2):315-6. PubMed ID: 18097237
    [No Abstract]   [Full Text] [Related]  

  • 4. Darunavir: after multiple antiretroviral treatment failure: another option.
    Prescrire Int; 2008 Jun; 17(95):109. PubMed ID: 18629967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model predictive control strategy toward optimal structured treatment interruptions in anti-HIV therapy.
    Pannocchia G; Laurino M; Landi A
    IEEE Trans Biomed Eng; 2010 May; 57(5):1040-50. PubMed ID: 20172797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.
    Gazzard BG; Anderson J; Babiker A; Boffito M; Brook G; Brough G; Churchill D; Cromarty B; Das S; Fisher M; Freedman A; Geretti AM; Johnson M; Khoo S; Leen C; Nair D; Peters B; Phillips A; Pillay D; Pozniak A; Walsh J; Wilkins E; Williams I; Williams M; Youle M;
    HIV Med; 2008 Oct; 9(8):563-608. PubMed ID: 18826546
    [No Abstract]   [Full Text] [Related]  

  • 7. Resistance to antiretroviral drugs: a threat to the prevention and treatment of pediatric HIV infection.
    Krogstad PA
    J Infect Dis; 2007 May; 195(10):1393-5. PubMed ID: 17436216
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antiretroviral therapy suppression: already a new strategy?].
    Viciana Fernández P; Mata Alcázar-Caballero R; López Cortés LF
    Farm Hosp; 2004; 28(6 Suppl 1):85-91. PubMed ID: 15649120
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years.
    Cuzin L; Delpierre C; Gerard S; Massip P; Marchou B
    Clin Infect Dis; 2007 Sep; 45(5):654-7. PubMed ID: 17683004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antiretroviral therapy of HIV infection. German-Austrian guidelines (position in September 2008)].
    ;
    Dtsch Med Wochenschr; 2009 Jan; 134 Suppl 1():S4-15. PubMed ID: 19172554
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent therapy for the treatment of chronic HIV infection.
    Ananworanich J; Hirschel B
    AIDS; 2007 Jan; 21(2):123-34. PubMed ID: 17197802
    [No Abstract]   [Full Text] [Related]  

  • 13. Trying to make sense of treatment interruptions.
    Lewis D; Sutton RE
    Res Initiat Treat Action; 2003; 9(2):14-5. PubMed ID: 14989200
    [No Abstract]   [Full Text] [Related]  

  • 14. Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?'.
    Hastings IM; Lalloo DG; Khoo SH
    AIDS; 2007 Jan; 21(2):258-9; author reply 259-60. PubMed ID: 17197825
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HIV-infection].
    Wasmuth JC; Rockstroh JK
    Dtsch Med Wochenschr; 2007 Mar; 132(13):673-83; quiz 685-6. PubMed ID: 17377882
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment strategies for highly treatment-experienced HIV-infected patients.
    Luber AD
    Expert Rev Anti Infect Ther; 2005 Oct; 3(5):815-23. PubMed ID: 16207173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
    Nüesch R; Ananworanich J; Srasuebkul P; Chetchotisakd P; Prasithsirikul W; Klinbuayam W; Mahanontharit A; Jupimai T; Ruxrungtham K; Hirschel B
    AIDS; 2008 Jan; 22(1):152-4. PubMed ID: 18090405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ask the experts.
    Kaiser JD
    Explore (NY); 2006; 2(5):471-2. PubMed ID: 16979115
    [No Abstract]   [Full Text] [Related]  

  • 20. The long-term consequences of antiretroviral therapy.
    Smith D
    J HIV Ther; 2006 Jun; 11(2):24-5. PubMed ID: 16981592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.